Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PAR1 contributes to influenza A virus pathogenicity in mice
Khaled Khoufache, … , Stephan Ludwig, Béatrice Riteau
Khaled Khoufache, … , Stephan Ludwig, Béatrice Riteau
Published December 3, 2012
Citation Information: J Clin Invest. 2013;123(1):206-214. https://doi.org/10.1172/JCI61667.
View: Text | PDF
Research Article Inflammation Article has an altmetric score of 16

PAR1 contributes to influenza A virus pathogenicity in mice

  • Text
  • PDF
Abstract

Influenza causes substantial morbidity and mortality, and highly pathogenic and drug-resistant strains are likely to emerge in the future. Protease-activated receptor 1 (PAR1) is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. The role of PAR1 in pathogenesis of virus infections is unknown. Here, we demonstrate that PAR1 contributed to the deleterious inflammatory response after influenza virus infection in mice. Activating PAR1 by administering the agonist TFLLR-NH2 decreased survival and increased lung inflammation after influenza infection. Importantly, both administration of a PAR1 antagonist and PAR1 deficiency protected mice from infection with influenza A viruses (IAVs). Treatment with the PAR1 agonist did not alter survival of mice deficient in plasminogen (PLG), which suggests that PLG permits and/or interacts with a PAR1 function in this model. PAR1 antagonists are in human trials for other indications. Our findings suggest that PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and oseltamivir-resistant H1N1 viruses.

Authors

Khaled Khoufache, Fatma Berri, Wolfgang Nacken, Annette B. Vogel, Marie Delenne, Eric Camerer, Shaun R. Coughlin, Peter Carmeliet, Bruno Lina, Guus F. Rimmelzwaan, Oliver Planz, Stephan Ludwig, Béatrice Riteau

×

Figure 5

PAR1 antagonist inhibits lung inflammation and virus replication.

Options: View larger image (or click on image) Download as PowerPoint
PAR1 antagonist inhibits lung inflammation and virus replication.
(A) Cy...
(A) Cytokines in the BAL of infected mice treated or not with SCH79797 were measured by ELISA 24, 48, and 72 hours after inoculation. Data are average ± SD from 7–11 individual animals per group, representative of 3 experiments. (B) Relative PMN frequency in BAL from infected mice treated or not with SCH79797. PMN percentage was determined by May-Grünwald–Giemsa staining 24, 48, and 72 hours after inoculation. Data are average ± SD from 3–5 individual mice per group. Noninfected mice were used as control (n = 3–5 per group). Results are representative of 2 individual experiments. (C) Virus titers in lungs of infected mice at the indicated times after infection with 500 PFU H1N1 and treatment with SCH79797. Data are average ± SD from 3–5 individual animals per group. *P < 0.05, treated vs. control, Mann-Whitney test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Posted by 6 X users
Referenced in 1 patents
On 1 Facebook pages
60 readers on Mendeley
See more details